Evercore Maintains Amgen(AMGN.US) With Buy Rating
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $383
TD Cowen Reaffirms Their Buy Rating on Amgen (AMGN)
Express News | Amgen : Deutsche Bank Cuts Target Price to $285 From $305
The strongest competitor's data is not good, will the 'weight-loss duo' continue to dominate?
Analysts believe that if Amgen's weight loss drug could achieve a 20% weight loss effect a few years ago, it would have been the best among similar products, but now Eli Lilly and Co and Novo-Nordisk A/S pipeline drugs may achieve or exceed a 25% weight loss effect. Currently, dozens of pharmaceutical companies are actively entering the weight loss drug market, but none have shown the potential to truly challenge the 'weight loss giants'.
Amgen Inc. (AMGN): A Bull Case Theory